JUNS
JUPITER NEUROSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.82
−2.93%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -61.4%
- EBIT
- -70.5%
- EPS
- —
- Free cash flow
- -28.8%
- Operating cash flow
- -28.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +132.6%
- EPS
- +100.0%
Three-year CAGR
- Revenue
- -54.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -38.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026